Please login to the form below

Not currently logged in
Email:
Password:

Bone Therapeutics strengthens board with new chairman

Jean Stéphenne joins the cell therapy company from TiGenix

Belgian biotechnology company Bone Therapeutics has appointed Jean Stéphenne as its new chairman of the board of directors, succeeding Steve Swinson in the process.

Stéphenne’s career history has seen him serve in senior leadership roles at several biotechnology and pharmaceutical companies, most recently as chairman of TiGenix.

He has also been a member of the corporate executive team for GlaxoSmithKline and chief executive officer of GSK Biologicals (now GSK Vaccines).

Thomas Lienard, chief executive officer of Bone Therapeutics, said: “Stéphenne has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector.

“He will be a valuable addition to an already strong board as we advance our allogeneic cell therapy platform through clinical studies.”

26th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics